Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Denbury (DNR) Q1 Earnings Beat, Sales Lag, Stock Down 5.8%

Published 05/07/2019, 10:49 PM
Updated 07/09/2023, 06:31 AM
APA
-
HES
-
NG
-
DEN
-
WHD
-

Denbury Resources Inc. (NYSE:DNR) reported earnings of 10 cents per share in first-quarter 2019 (excluding one-time items), beating the Zacks Consensus Estimate of 8 cents on the back of higher commodity price realizations. However, the bottom line declined from the year-ago figure of 12 cents, primarily due to higher expenses.

Total revenues were $305.5 million, down from $353.2 million in the year-ago quarter. Also, the top line missed the Zacks Consensus Estimate of $312 million. Notably, sales were affected by lower production volumes.

The stock tumbled 5.8% yesterday following the company’s earnings release, as overall results failed to impress investors.

Denbury Resources Inc. Price, Consensus and EPS Surprise

Denbury Resources Inc. Price, Consensus and EPS Surprise | Denbury Resources Inc. Quote

Operational Performance

Production Declines

During the quarter, production averaged 59,218 barrels of oil equivalent per day (Boe/d) compared with 60,338 Boe/d in the prior-year period.

Oil production averaged 57,414 barrels per day (BPD), down from the year-ago level of 58,354 BPD. Natural gas daily production averaged 10,827 thousand cubic feet (Mcf/d), lower than the year-ago period’s 11,904 Mcf/d.

The company’s production from tertiary operations averaged 37,073 Boe/d, down from 38,262 Boe/d in the year-ago quarter.

Price Realization Marginally Up

Oil price realization (including the impact of hedges) averaged $58.09 per barrel in the quarter, marginally increasing from the year-ago level of $57.89. Gas prices rose to $2.68 per Mcf from $2.44 in the year-ago quarter. On an oil-equivalent basis, overall price realization was $56.81 per barrel, slightly higher than the year-earlier level of $56.47.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Total Expenses Rise

During the quarter, total expenses were $341.9 million, up from $299.6 million in the year-ago period. The surge can be attributed to higher lease operating expenses, which resulted from increased CO2 costs.

Capital Expenditure

Oil and natural gas capital investments were approximately $59.6 million compared with $47.3 million in the year-ago quarter. Total capital spending (excluding capitalized interest) was $61.2 million, higher than $47.7 million in first-quarter 2018.

Financials

Cash flow from operations was $64.4 million, down from $91.6 million in the year-ago quarter.

As of Mar 31, 2019, cash balance was $5.7 million and total debt was $2,525.7 million. It also had a bank credit facility of $615 million.

Guidance

Denbury expects to generate more than $150 million of free cash flow in full-year 2019. The company reiterated its 2019 production guidance in the range of 56,000-60,000 Boe/d. Capital expenditure is estimated in the range of $240-$260 million, down 20-25% from the 2018 capital spending level.

Zacks Rank and Stocks to Consider

Currently, Denbury carries a Zacks Rank #3 (Hold). Prospective players in the energy space worth considering include Cactus, Inc. (NYSE:WHD) , Hess Corporation (NYSE:HES) and Apache Corporation (NYSE:APA) , each holding a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Cactus’ earnings growth is projected at 11.8% through 2019.

Hess’ earnings are expected to grow 90.5% through 2019.

Apache beat the Zacks Consensus Estimate in each of the last four quarters, with average positive earnings surprise of 31%.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Denbury Resources Inc. (DNR): Free Stock Analysis Report

Apache Corporation (APA): Free Stock Analysis Report

Hess Corporation (HES): Free Stock Analysis Report

Cactus, Inc. (WHD): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.